Ernest Loumaye

Jump to navigation Jump to search
Ernest Loumaye
Born1952 (age 69–70)
NationalityBelgian
Known forCo-founder and CEO of ObsEva

Ernest Loumaye is a Belgian entrepreneur known for his works in the women's health care industry. He is the co-founder and CEO of ObsEva, a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for severe medical conditions relating to women’s reproductive and pregnancy health.[1][2]

Loumaye holds an M.D. and Ph.D. from Louvain University, with a specialization in Obstetrics and Gynecology. Loumaye began his career as the gynecologist in charge of the reproductive unit at Université catholique de Louvain (UCLouvain), university hospital in Brussels, Belgium.[3]

In 2006, he co-founded Preglem SA, a Swiss specialty biopharmaceutical company, where he served as the CEO from 2006 to 2012. It worked to develop and commercialize women's reproductive medicine. PregLem’s leading drug helped women suffering from fibroids, a condition where noncancerous growths in the uterus develop during a woman’s childbearing years. In total, PregLem raised over 68 million Swiss francs (Fr.) (US$71 million) in funding and eventually sold in 2010 for Fr. 445 million ($465 million) to eastern European pharmaceutical company Richter Gedeon.[4][5][6]

Loumaye is also the chairman of the board of directors of GenKyoTex S.A., a private Swiss pharmaceutical company.[7]

After PregLem, Loumaye co-founded ObsEva in 2012. Like PregLem, ObsEva is a company focused on women’s reproductive health. It deals with health issues relating to women by producing drugs that address conditions from conception to birth. The company, ObsEva is headquartered in Geneva, Switzerland, and is a listed company on NASDAQ since January 2017.[8][9][10]

References[edit]

  1. ^ "Ernest Loumaye M.D., Ph.D., OB/GYN: Executive Profile & Biography - Bloomberg". www.bloomberg.com. Retrieved 26 August 2017.
  2. ^ "Time to address unmet need in women's reproductive health". www.europeanpharmaceuticalreview.com. Retrieved 26 August 2017.
  3. ^ "Ernest Loumaye is the Gynecologist Helming Geneva's Star Biotech ObsEva". Labiotech.eu. 26 June 2017. Retrieved 26 August 2017.
  4. ^ Grogan, Kevin (8 October 2010). "Hungary's Gedeon Richter buys PregLem". www.pharmatimes.com. Retrieved 26 August 2017.
  5. ^ "PregLem - About Us - PregLem.com". PregLem.com. Retrieved 26 August 2017.
  6. ^ "How to raise CHF100 million Startupticker.ch | The Swiss Startup News channel". www.startupticker.ch. Retrieved 26 August 2017.
  7. ^ "Ernest Loumaye of ObsEva SA Board of Directors". insiders.morningstar.com. Retrieved 26 August 2017.
  8. ^ "ObsEva SA Ordinary Shares (OBSV)". NASDAQ.com. Retrieved 6 September 2017.
  9. ^ Jones, Donovan (10 January 2017). "ObsEva Initiates IPO Filing For Women's Reproductive Treatments". Seeking Alpha. Retrieved 26 August 2017.
  10. ^ "ObsEva taps A-list investors for $60M as pipeline nears late-phase trials | FierceBiotech". www.fiercebiotech.com. Retrieved 26 August 2017.